Theravance Biopharma Inc. [TBPH] moved down -14.78: Why It’s Important

Related

Theravance Biopharma Inc. [NASDAQ: TBPH] loss -14.78% or -1.65 points to close at $9.51 with a heavy trading volume of 6082787 shares. The company report on January 10, 2022 that Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced enrollment of the first patient in a Phase 4 study of YUPELRI® (revefenacin) inhalation solution, the first and only once-daily, nebulized bronchodilator approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Success in this study is intended to capture more of YUPELRI’s addressable market and further strengthen its competitive advantage.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


“YUPELRI, discovered and developed by Theravance, is one of the key pillars of value creation for the go-forward organization. We, and our partner Viatris, believe we have just scratched the surface of YUPELRI’s contribution to the COPD community,” said Rick E Winningham, Chief Executive Officer. “The enrollment of the first patient in the Phase 4 PIFR-2 study demonstrates, through continued investment in controlled clinical studies, our commitment to provide healthcare professionals with the evidence needed to design personalized treatment plans in order to make better informed decisions for their COPD patients.” .

It opened the trading session at $11.06, the shares rose to $11.15 and dropped to $9.42, the range by which the price of stock traded the whole day. The daily chart for TBPH points out that the company has recorded -30.18% loss over the past six months. However, it is still -55.9% lower than its most recent low trading price.

If we look at the average trading volume of 1.02M shares, TBPH reached to a volume of 6082787 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Theravance Biopharma Inc. [TBPH]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TBPH shares is $10.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TBPH stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

JP Morgan have made an estimate for Theravance Biopharma Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 05, 2021. The new note on the price target was released on September 15, 2021, representing the official price target for Theravance Biopharma Inc. stock. Previously, the target price had yet another drop from $27 to $14, while Morgan Stanley kept a Underweight rating on TBPH stock. On August 24, 2021, analysts decreased their price target for TBPH shares from 42 to 14.

The Average True Range (ATR) for Theravance Biopharma Inc. is set at 0.92, with the Price to Sales ratio for TBPH stock in the period of the last 12 months amounting to 11.64.

Trading performance analysis for TBPH stock

Theravance Biopharma Inc. [TBPH] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -21.99. With this latest performance, TBPH shares dropped by -5.18% in over the last four-week period, additionally sinking by -30.18% over the last 6 months – not to mention a drop of -45.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TBPH stock in for the last two-week period is set at 39.43, with the RSI for the last a single of trading hit 31.39, and the three-weeks RSI is set at 44.31 for Theravance Biopharma Inc. [TBPH]. The present Moving Average for the last 50 days of trading for this stock 9.62, while it was recorded at 11.83 for the last single week of trading, and 12.87 for the last 200 days.

Theravance Biopharma Inc. [TBPH]: A deeper dive into fundamental analysis

Operating Margin for any stock indicates how profitable investing would be, and Theravance Biopharma Inc. [TBPH] shares currently have an operating margin of -414.37. Theravance Biopharma Inc.’s Net Margin is presently recorded at -386.90.

Return on Total Capital for TBPH is now -90.34, given the latest momentum, and Return on Invested Capital for the company is -90.80. Additionally, TBPH Total Debt to Total Capital is recorded at 181.54, with Total Debt to Total Assets ending up at 144.17.

Reflecting on the efficiency of the workforce at the company, Theravance Biopharma Inc. [TBPH] managed to generate an average of -$774,421 per employee. Receivables Turnover for the company is 1.20 with a Total Asset Turnover recorded at a value of 0.16.Theravance Biopharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.50 and a Current Ratio set at 4.50.

>> 7 Top Picks for the Post-Pandemic Economy <<

An analysis of insider ownership at Theravance Biopharma Inc. [TBPH]

There are presently around $576 million, or 84.60% of TBPH stock, in the hands of institutional investors. The top three institutional holders of TBPH stocks are: BAUPOST GROUP LLC/MA with ownership of 13,660,168, which is approximately 37.84% of the company’s market cap and around 5.90% of the total institutional ownership; ORBIMED ADVISORS LLC, holding 5,895,159 shares of the stock with an approximate value of $56.06 million in TBPH stocks shares; and VANGUARD GROUP INC, currently with $55.7 million in TBPH stock with ownership of nearly 10.941% of the company’s market capitalization.

Positions in Theravance Biopharma Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 76 institutional holders increased their position in Theravance Biopharma Inc. [NASDAQ:TBPH] by around 23,630,751 shares. Additionally, 43 investors decreased positions by around 23,329,973 shares, while 20 investors held positions by with 13,634,223 shares. The mentioned changes placed institutional holdings at 60,594,947 shares, according to the latest SEC report filing. TBPH stock had 33 new institutional investments in for a total of 13,503,024 shares, while 24 institutional investors sold positions of 5,010,284 shares during the same period.